Title:
標的ＯＸ４０アゴニストとの併用療法
Document Type and Number:
Japanese Patent JP2021501162
Kind Code:
A
Abstract:
本発明は、腫瘍関連抗原に特異的なＴ細胞活性化抗ＣＤ３二重特異性抗体と組み合わせた腫瘍標的二重特異性ＯＸ４０抗体、特に抗ＦＡＰ／抗ＯＸ４０抗体を用いた併用療法、がんの治療のためのこれらの併用療法の使用、及び併用療法の使用方法に関する。【選択図】図１９Ａ
Inventors:
Bacak, Marina
Grau-Richards, Zandra
Klein, Christian
Sam, Johannes
Umagna, Pablo
Lang, Sabine
Aman, Maria
Pincha, mudita
Grau-Richards, Zandra
Klein, Christian
Sam, Johannes
Umagna, Pablo
Lang, Sabine
Aman, Maria
Pincha, mudita
Application Number:
JP2020523768A
Publication Date:
January 14, 2021
Filing Date:
October 31, 2018
Export Citation:
Assignee:
Ef Hoffman-La Roche Akchengezel Shaft
International Classes:
C07K16/28; A61K9/08; A61K9/19; A61K39/395; A61P35/00; A61P43/00; C07K16/46; C12N15/13
Domestic Patent References:
| JP2016508723A | 2016-03-24 |
Foreign References:
| WO2017060144A1 | 2017-04-13 | |||
| WO2016079076A1 | 2016-05-26 |
Other References:
PLOS ONE, vol. 9(2), JPN6022040979, 2014, pages 89350 - 1, ISSN: 0004888218
CLIN CANCER RES., vol. 23(20), JPN6022040977, 15 October 2017 (2017-10-15), pages 6165 - 6177, ISSN: 0004888219
CLIN CANCER RES., vol. 19(22), JPN6022040976, 2013, pages 6151 - 6162, ISSN: 0004888220
CLIN CANCER RES., vol. 23(20), JPN6022040977, 15 October 2017 (2017-10-15), pages 6165 - 6177, ISSN: 0004888219
CLIN CANCER RES., vol. 19(22), JPN6022040976, 2013, pages 6151 - 6162, ISSN: 0004888220
Attorney, Agent or Firm:
Sonoda/Kobayashi Patent Business Corporation